Implications for Research and Policy
viremia
VIREMIA
Our findings suggest that a larger randomized trial of point-of-care VL testing to manage viremia may be feasible, but would likely need to be conducted at multiple sites to ensure adequate enrolment. Furthermore, our findings highlight the difficulty in evaluating diagnostic interventions that require changes in clinical flow, without inadvertently improving standard of care. Cluster-randomized trials may be more appropriate for evaluating this kind of intervention, although it is harder to generate small-scale preliminary data. In the context of the ongoing dolutegravir-based ART rollout, the opportunity for point-of-care testing to influence management of viremia